295 related articles for article (PubMed ID: 33855595)
1. Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.
Benzerdjeb N; Dartigues P; Kepenekian V; Valmary-Degano S; Mery E; Avérous G; Chevallier A; Laverriere MH; Villa I; Harou O; Sallé FG; Villeneuve L; Glehen O; Isaac S; Hommell-Fontaine J; Bibeau F;
Virchows Arch; 2021 Oct; 479(4):765-772. PubMed ID: 33855595
[TBL] [Abstract][Full Text] [Related]
2. Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study.
Benzerdjeb N; Dartigues P; Kepenekian V; Valmary-Degano S; Mery E; Averous G; Chevallier A; Laverriere MH; Villa I; Sallé FG; Villeneuve L; Glehen O; Isaac S; Hommell-Fontaine J;
Virchows Arch; 2021 Nov; 479(5):927-936. PubMed ID: 34169365
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Valmary-Degano S; Colpart P; Villeneuve L; Monnien F; M'Hamdi L; Lang Averous G; Capovilla M; Bibeau F; Laverriere MH; Verriele-Beurrier V; Ben Rejeb H; Dartigues P; Hommell-Fontaine J; Gilly FN; Isaac S; Mery E;
Eur J Surg Oncol; 2017 Oct; 43(10):1915-1923. PubMed ID: 28619621
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
5. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.
Liu S; Staats P; Lee M; Alexander HR; Burke AP
Pathology; 2014 Dec; 46(7):604-9. PubMed ID: 25393250
[TBL] [Abstract][Full Text] [Related]
6. Define the Two Molecular Subtypes of Epithelioid Malignant Pleural Mesothelioma.
Saddozai UAK; Wang F; Khattak S; Akbar MU; Badar M; Khan NH; Zhang L; Zhu W; Xie L; Li Y; Ji X; Guo X
Cells; 2022 Sep; 11(18):. PubMed ID: 36139498
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.
Krasinskas AM; Borczuk AC; Hartman DJ; Chabot JA; Taub RN; Mogal A; Pingpank J; Bartlett D; Dacic S
Histopathology; 2016 Apr; 68(5):729-37. PubMed ID: 26272336
[TBL] [Abstract][Full Text] [Related]
8. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
Lee M; Alexander HR; Burke A
Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
[TBL] [Abstract][Full Text] [Related]
9. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
[TBL] [Abstract][Full Text] [Related]
10. Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
[TBL] [Abstract][Full Text] [Related]
11. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
Chapel DB; Schulte JJ; Absenger G; Attanoos R; Brcic L; Butnor KJ; Chirieac L; Churg A; Galateau-Sallé F; Hiroshima K; Hung YP; Kindler H; Krausz T; Marchevsky A; Mino-Kenudson M; Mueller J; Nabeshima K; Turaga K; Walts AE; Husain AN
Mod Pathol; 2021 Feb; 34(2):380-395. PubMed ID: 33060816
[TBL] [Abstract][Full Text] [Related]
12. Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion.
Kato K; Gemba K; Fujimoto N; Aoe K; Takeshima Y; Inai K; Kishimoto T
Eur J Radiol; 2016 Sep; 85(9):1594-600. PubMed ID: 27501894
[TBL] [Abstract][Full Text] [Related]
13. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
14. Malignant peritoneal mesothelioma in patients with endometriosis.
Butnor KJ; Rueckert J; Pavlisko EN; Sporn TA; Roggli VL
J Clin Pathol; 2018 Nov; 71(11):971-974. PubMed ID: 29794065
[TBL] [Abstract][Full Text] [Related]
15. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
16. Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study.
Mannarino L; Paracchini L; Pezzuto F; Olteanu GE; Moracci L; Vedovelli L; De Simone I; Bosetti C; Lupi M; Amodeo R; Inglesi A; Callari M; Penpa S; Libener R; Delfanti S; De Angelis A; Muzio A; Zucali PA; Allavena P; Ceresoli GL; Marchini S; Calabrese F; D'Incalci M; Grosso F
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628597
[TBL] [Abstract][Full Text] [Related]
17. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
[TBL] [Abstract][Full Text] [Related]
18. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
[TBL] [Abstract][Full Text] [Related]
19. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
20. Primary Malignant Deciduoid Mesothelioma: A Challenging Diagnosis.
Regragui M; Guebessi NB
Arch Pathol Lab Med; 2019 Apr; 143(4):531-533. PubMed ID: 30500290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
